Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2019 Earnings Conference Call - Final Transcript
Feb 26, 2020 • 05:00 pm ET
Good morning and welcome to Editas Medicine's Fourth Quarter and Full-Year 2019 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the Company's request.
I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at Editas Medicine.
Mark J. Mullikin
Thank you, operator. Good morning, everyone, and welcome to our fourth quarter and full-year 2019 conference call.
Shortly after the market closed, we issued a press release providing our financial results and corporate updates for the fourth quarter and full-year 2019.
A replay of today's call will be available on the Investors and Media section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A.
As a reminder, various remarks that we make during this call about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10-K, which is on file with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change.
Now, I will turn the call over to our Chief Executive Officer, Cindy Collins.
Cynthia L. Collins
Thank you, Mark. Good afternoon and thank you, everyone, for joining us for our corporate update call for the fourth quarter and full-year 2019. In addition to Mark, I'm joined by several members of the Editas executive team, including Judith Abrams, our Chief Medical Officer; Charlie Albright, our Chief Scientific Officer; Michelle Robertson, our new Chief Financial Officer, and Tim Hunt, our Senior Vice President of Corporate Affairs.
We are at an exciting point at Editas Medicine, developing differentiated, transformational medicines across a range of serious diseases and nearing the point of seeing them work in patients. On today's call, we will review some of what we have achieved over the past year, then look ahead to 2020 and beyond.
So let's start with some of our accomplishments over the past year. We initiated the first ever clinical trial of an in vivo CRISPR medicine in collaboration with Allergan of EDIT-101 for patients with LCA10. We started IND-enabling studies for EDIT-301 as a potentially best-in-class medicine for the treatment of sickle cell disease. We amended our collaboration with Celgene, now part of Bristol-Myers Squibb, to focus on developing engineered alpha beta T cell medicines for cancer. We are excited to continue our work with the leader in treating blood cancers. With the amendment, we received a $70 million cash payment and regained rights to develop engineered gamma T cell medicines in